Sima Saberi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sima Saberi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Nazanene H. Esfandiari
Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, MI
2 shared publicationsCarol A. Janney
Consulting for Statistics, Computing and Analytics Research (CSCAR), University of Michigan, Ann Arbor, MI
1 shared publicationDavid Shlensky
Radiology Associates of the Fox Valley S.C., Neenah, Wisconsin
1 shared publicationDavid T. Hughes
Department of Surgery, University of Michigan, Ann Arbor, MI
1 shared publicationFirdhous Abdul Kather
MDWell.com, Livonia MI
1 shared publicationGregory A. Clines
Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, MI
1 shared publication
Latest Publications
- 19 December 2025
- Published by Elsevier in Endocrine Practice
- Vol. 32 (4) , 565-569
Postparathyroidectomy Bone Density Changes in Patients With Biochemically Mild Primary Hyperparathyroidism
- 19 December 2025
- Published by Elsevier in Endocrine Practice
- Vol. 32 (4) , 565-569
Postparathyroidectomy Bone Density Changes in Patients With Biochemically Mild Primary Hyperparathyroidism
- Open Access
- 7 November 2024
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 2 (12) , luae209
Calcitriol-Mediated Hypercalcemia Due to Liver Metastases in a Patient With Primary Pancreatic Neuroendocrine Tumor
Hypercalcemia is most commonly associated with primary hyperparathyroidism or malignancy in the setting of elevated parathyroid hormone-related protein or bone metastases. Calcitriol (1,25-dihydroxyvitamin D)-mediated hypercalcemia is rare and typically associated with granulomatous conditions; however, other solid-organ etiologies have been reported. Here, we detail the case of a 62-year-old man with metastatic pancreatic neuroendocrine tumor (pNET) with hypercalcemia refractory to traditional bisphosphonate therapy in the setting of vastly elevated 1,25-dihydroxyvitamin D. Only after initiation of chemotherapy with capecitabine and temozolomide did his serum calcium consistently improve and 1,25-dihydroxyvitamin D begin to decrease. There are fewer than 5 reported cases of a pNET resulting in calcitriol-mediated hypercalcemia. Prompt initiation of treatment for the underlying condition can result in a significant improvement in serum calcium or 1,25-dihydroxyvitamin D. Multiple reports have also demonstrated success with high-dose steroid administration in patients with other solid-organ etiologies of calcitriol-mediated hypercalcemia, but this has not yet been reviewed in the pNET population.
- 7 November 2024
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 2 (12) , luae209
Open AccessCalcitriol-Mediated Hypercalcemia Due to Liver Metastases in a Patient With Primary Pancreatic Neuroendocrine Tumor
Hypercalcemia is most commonly associated with primary hyperparathyroidism or malignancy in the setting of elevated parathyroid hormone-related protein or bone metastases. Calcitriol (1,25-dihydroxyvitamin D)-mediated hypercalcemia is rare and typically associated with granulomatous conditions; however, other solid-organ etiologies have been reported. Here, we detail the case of a 62-year-old man with metastatic pancreatic neuroendocrine tumor (pNET) with hypercalcemia refractory to traditional bisphosphonate therapy in the setting of vastly elevated 1,25-dihydroxyvitamin D. Only after initiation of chemotherapy with capecitabine and temozolomide did his serum calcium consistently improve and 1,25-dihydroxyvitamin D begin to decrease. There are fewer than 5 reported cases of a pNET resulting in calcitriol-mediated hypercalcemia. Prompt initiation of treatment for the underlying condition can result in a significant improvement in serum calcium or 1,25-dihydroxyvitamin D. Multiple reports have also demonstrated success with high-dose steroid administration in patients with other solid-organ etiologies of calcitriol-mediated hypercalcemia, but this has not yet been reviewed in the pNET population.
- Open Access
- 26 March 2024
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 10 (4) , 123-126
Pulmonary Metastatic Follicular Thyroid Carcinoma Without Intrathyroidal Primary Thyroid Cancer
- 26 March 2024
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 10 (4) , 123-126
Open AccessPulmonary Metastatic Follicular Thyroid Carcinoma Without Intrathyroidal Primary Thyroid Cancer
- Open Access
- 10 November 2023
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 10 (1) , 31-32
Kissing Carotid Arteries Causing Male Hypogonadotropic Hypogonadism
- 10 November 2023
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 10 (1) , 31-32
Open AccessKissing Carotid Arteries Causing Male Hypogonadotropic Hypogonadism
- Open Access
- 1 July 2023
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2023 (7) , omad070
Cystic pheochromocytoma
A 67-year-old woman presented with right abdominal tenderness and distention, gas and belching. Her blood pressure was 134/70 and pulse was 84. Abdominal ultrasound (US) showed a mass. Abdominal computed tomography (CT) revealed a 10-cm predominantly cystic adrenal mass with partial irregular wall thickening and nodularity, causing mass effect on the inferior vena cava, liver and right kidney ( Fig. 1). She has a history of depression and anxiety which was diagnosed 17 years prior to presentation during a stressful period, which was then resolved. She has had hypertension since the 1990s, which was well controlled for 14 years with doses of candesartan-hydrochlorothiazide 16–12.5 mg daily and metoprolol succinate ER 50 mg daily. Two years prior to presentation, her blood pressure rose to the 180s/90s, requiring doubling of candesartan-hydrochlorothiazide. Labs showed plasma-free metanephrine 1187 pg/ml (normal, <57 pg/ml), plasma-free normetanephrine 1911 pg/ml (normal, <148 pg/ml) and total free metanephrine and normetanephrine 3098 pg/ml (normal, <205 pg/ml). Other adrenal hormone evaluation was normal. Nicardipine was initiated. Four weeks later, she underwent open right adrenalectomy resecting the pheochromocytoma confined to the adrenal gland without evidence of metastasis. Annual post-operative plasma metanephrines and normetanephrines remain normal.
- 1 July 2023
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2023 (7) , omad070
Open AccessCystic pheochromocytoma
A 67-year-old woman presented with right abdominal tenderness and distention, gas and belching. Her blood pressure was 134/70 and pulse was 84. Abdominal ultrasound (US) showed a mass. Abdominal computed tomography (CT) revealed a 10-cm predominantly cystic adrenal mass with partial irregular wall thickening and nodularity, causing mass effect on the inferior vena cava, liver and right kidney ( Fig. 1). She has a history of depression and anxiety which was diagnosed 17 years prior to presentation during a stressful period, which was then resolved. She has had hypertension since the 1990s, which was well controlled for 14 years with doses of candesartan-hydrochlorothiazide 16–12.5 mg daily and metoprolol succinate ER 50 mg daily. Two years prior to presentation, her blood pressure rose to the 180s/90s, requiring doubling of candesartan-hydrochlorothiazide. Labs showed plasma-free metanephrine 1187 pg/ml (normal, <57 pg/ml), plasma-free normetanephrine 1911 pg/ml (normal, <148 pg/ml) and total free metanephrine and normetanephrine 3098 pg/ml (normal, <205 pg/ml). Other adrenal hormone evaluation was normal. Nicardipine was initiated. Four weeks later, she underwent open right adrenalectomy resecting the pheochromocytoma confined to the adrenal gland without evidence of metastasis. Annual post-operative plasma metanephrines and normetanephrines remain normal.